FULC Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

$4.92
As of 07/01/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/18/2019
Outstanding shares:  40,848,212
Average volume:  1,091,182
Market cap:   $200,156,239
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BJDX8Z9
Valuation   (See tab for details)
PE ratio:   -2.24
PB ratio:   1.06
PS ratio:   11.80
Return on equity:   -47.46%
Net income %:   -529.15%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy